Michael S. Wyzga
President & CEO

Mr. Wyzga is President and Chief Executive Officer of Radius. Prior to joining Radius, he was Executive Vice President, Finance and Chief Financial Officer of Genzyme until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the firm's financial management worldwide. He provided key leadership in the successful $20.1 billion sale of Genzyme to Sanofi, which was the second-largest acquisition in biotechnology history, following Roche's $46.8 billion purchase of Genentech in 2009. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.

Nick Harvey
Senior Vice President, Chief Financial Officer

Mr. Harvey is Senior Vice President and Chief Financial Officer of Radius. He has more than 15 years of experience in building and financing life sciences and technology businesses. Prior to joining Radius, he served for four years as Managing Director of Shiprock Capital, a venture capital firm, where he was responsible for deal-sourcing, negotiating and closing transactions, and developing strategic plans for portfolio companies. Before that, Mr. Harvey served as CFO of a number of venture-backed companies over a 10-year period, including Transfusion Technologies and Transcend Therapeutics. At Transfusion, he helped to close a major distribution agreement with Zimmer and oversaw the company’s acquisition by Haemonetics. During his tenure at Transcend, the company raised $25 million of venture capital and corporate financing, closed a $46 million worldwide licensing agreement with Boehringer Ingelheim, and completed an initial public offering on NASDAQ. Mr. Harvey holds an undergraduate degree in Economics, a law degree with first-class honors from the Australian National University, and an MBA from the Harvard Business School.

Michael Franken, MD
Senior Vice President, Chief Business Officer

Dr. Franken is Senior Vice President and Chief Business Officer of Radius. He has more than 15 years of life sciences leadership experience across strategy, commercial, and business development functions. Prior to joining Radius, he served as Vice President and General Manager, Solid Organ Transplantation, at Genzyme Corporation, where he was successful in building and significantly growing the transplant business to more than $260 million in revenues through focused development of the transplant products (including Thymoglobuline®) across multiple indications and expanding commercial markets globally. Since joining Genzyme in 2000, Dr. Franken held progressively senior positions in corporate development, program, and general management. In the area of Immune Diseases and Fibrosis, he was responsible for the company's preclinical and clinical development portfolio and for business development, where he successfully identified and executed several licensing and partnering transactions. He also provided leadership in establishing and managing Genzyme Ventures, Genzyme's corporate venture capital arm. Prior to joining Genzyme, Dr. Franken was a life sciences business consultant at The Wilkerson Group. He received an MD from the University of Heidelberg, Germany and a Master in Health Policy and Management from Harvard University's School of Public Health.

C. Richard Lyttle, PhD
Chief Scientific Officer

Dr. Lyttle currently serves as Chief Scientific Officer of Radius following his retirement as President and CEO in December 2011. Previously, he was Vice President of Discovery for Women's Health and Bone as well as Head of the Women's Health Research Institute at Wyeth. At Wyeth, he directed drug discovery in women's health for several areas including menopause, contraception, reproductive disorders, osteoarthritis, osteoporosis, and urinary incontinence. Under his leadership, Wyeth advanced 17 new product candidates into preclinical and clinical development, including the SERM, bazedoxifene; Tanaproget, a novel non-steroidal contraceptive; and DVS-233 for vasomotor symptoms associated with menopause. Prior to joining Wyeth, Dr. Lyttle was Research Professor of Obstetrics, Gynecology, and Pharmacology at the University of Pennsylvania. He received a PhD in Biochemistry from Queen's University, Kingston, Ontario, followed by postdoctoral research at the Population Council at the Rockefeller University, the Department of Biology at Queen's University, and the University of Chicago.

Louis Brenner, MD
Chief Medical Officer

Louis Brenner, MD, joins Radius after serving as Senior Vice President at AMAG Pharmaceuticals, where he was responsible for the Phase 3 studies and the successful regulatory submission for Feraheme®. Prior to that, he served in progressively senior roles at Genzyme, where he advanced the development and commercialization of products to treat metabolic bone disease by co-inventing the formulation for Renvela®, an oral phosphate binder to treat hyperphosphatemia, and by leading the acquisition of Bone Care International, manufacturer of Hectorol®, a synthetic Vitamin D analog for the treatment of hyperparathyroidism. He also previously served as a Director of PLC Medical Systems. Dr. Brenner is board-certified in Nephrology and cares for patients at Brigham and Women's Hospital in Boston, and he is a lecturer in Medicine at Harvard Medical School. He received a BS in Biology from Yale University, an MD from Duke University, and an MBA from Harvard Business School.

Gary Hattersley, PhD
Senior Vice President, Preclinical Development

Dr. Hattersley is Senior Vice President, Preclinical Development at Radius. He has more than 20 years of experience in musculoskeletal research and is the author of numerous scientific publications related to bone biology and physiology. Prior to joining Radius, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals with responsibility for the discovery and development of novel small-molecule agents for the treatment of osteoporosis and other metabolic bone diseases. Dr. Hattersley also held positions at Genetics Institute/Wyeth Research investigating the application of the bone morphogenetic proteins in bone and connective tissue repair and regeneration. Dr. Hattersley received a PhD in Experimental Pathology from St. George's Hospital Medical School in London.